Close Menu

NEW YORK – Researchers in the US and Japan have found that the overexpression of certain biomarkers associated with the cancer-immunity cycle in the pan-cancer setting was significantly associated with shorter progression-free survival (PFS) after anti-PD1/PD-L1-based therapies.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.